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Abstract
One out of four patients affected by COVID-19 will experience persistent 
(>3-4 weeks) signs and symptoms (Post COVID-19 conditions or Post-Acute Sequelae of 
SARS-CoV-2 – PASC) and this fact will have a major significance for the healthcare and 
economic systems in the upcoming years. The cardiovascular system is one of the key tar-
gets for the Post COVID-19 syndrome, given the pathogenesis of the virus and prevalence 
of ACE-2 receptors. According to our initial personal experience via the campaign “Life 
after COVID” of the Bulgarian Cardiac Institute, a substantial proportion of patients 
having suffered from COVID-19 develop long-term cardiovascular consequences. They 
could range from rhythm disorder and blood pressure variation, through impairment 
of myocardial mechanics and heart failure, and to acute vascular manifestations of Post 
COVID-19 conditions, such as acute coronary syndrome, acute pulmonary embolism, 
and acute limb ischemia. These cardiovascular complications require special and 
 dedicated medical attention, and we could share our personal experience on the matter.
Keywords: post COVID-19 conditions, cardio-vascular system,  
acute coronary syndrome, acute pulmonary embolism
1. Introduction
1.1 Definition
According to its definition, post COVID-19 conditions comprise all signs and 
symptoms of COVID-19 that persist after the acute phase (3 to 4 weeks), without 
an upper limit of duration (as for the present state of knowledge). Another term 
for these conditions, introduced by Antoni Fauci, is “Post-Acute Consequences of 
SARS-CoV-2 Infection” (PASC) [1].
1.2 Time frame
The acute phase of the disease usually lasts about 3-4 weeks from the onset of 
symptoms, after which replication competent SARS-CoV-2 has not been isolated in 
the nasopharynx [1].
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Accumulated data show that the consequences for the body can be just as serious 
and continue for an unusually long time after the initial encounter with the virus. It 
is the long persistence of complaints of varying degrees and manifestations after the 
infection that are known as post COVID-19 conditions. There is no precise scientific 
definition for the reason, duration, and prognosis of PASC [2].
The acute phase of the disease does not determine the onset of Post COVID-19 
syndrome, because even patients with mild or asymptomatic infection may report 
PASC. There is no age limit for the manifestation of post Covid-19 conditions, but 
the reported frequency is higher in the elderly population [3, 4].
According to the latest data from the World Health Organization, the conse-
quences of an infectious disease can last for two to three years [5].
1.3 Pathogenetic considerations
There are several pathogenetic hypotheses for PASС. The first is direct cell 
damage by binding of SARC-CoV-2 to ACE 2, initiating a violent immune 
response leading to increased cytokine production and triggering of procoagulant 
states [6].
It was later found that the reason for prolonged viral replication is the fact that 
SARS-CoV-2 can be transmitted by a different route from the respiratory tract, 
namely through the gastrointestinal tract, which could be considered a second 
hypothesis. The gastrointestinal tract is a major immunological organ in the human 
body and disruption of its microbiome leads to severe dysbacteriosis. Intestinal 
inflammation exacerbates the expression of ACE2, and the virus stays in the gut for 
much longer, which in turn can modulate immune responses and cause prolonged 
symptoms [6, 7]. This has been demonstrated by an intestinal biopsy, which detects 
the presence of the virus for months [7].
COVID-19 has also been shown to provoke autoimmune reactions, leading to a 
more severe course of the disease and the development of post COVID-19 condi-
tions [7].
The suboptimal immune response leads to a higher viral load associated 
with decreased balance in interferon production. It was found that in severe 
disease the body lacks IFN-beta and the level of IFN-alpha and lambda is 
reduced [7, 8].
Lymphopenia and unregulated inflammation have been observed in patients 
with severe COVID-19 and prolonged persistence of the infection as a result of 
decreased production of granular lymphocytes (NK cells), CD16 + monocytes, 
plasmacytoid dendritic cells, which are responsible for innate immunity [8].
1.4 Symptoms
The severity of symptoms can range from mild to inability to perform normal 
daily duties. Every system could be involved, with a typical fluctuation and chang-
ing of symptoms over time. As the pathogenesis has shown, prolonged exposure to 
viral load can cause multisystem inflammatory syndrome (MIS) or trigger autoim-
mune conditions. The involvement in PASC is multi-organ, with the most common 
being complaints from the nervous system [2, 9]. Post COVID-19 conditions are 
more common among people with chronic diseases such as hypertension, diabe-
tes, kidney disease, obesity. Genetic pre-exposure to the disease has not yet been 
specified.
The main systems that are affected are the nervous, cardiovascular, pulmonary, 
and excretory systems, musculoskeletal system, skin (Table 1).
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System Symptoms Sign
Neuropsychiatric fatigue, dizziness, headache, 
dysautonomia and cognitive 
impairment (brain fog), 
anxiety, depression, sleep 
disturbances
Direct damage to nerve tissue by the virus in 
patients with severe disease. [2] Psycho-emotional 
changes may include a wide range of symptomatic 
complexes characteristic of severe patients who 
are being treated in intensive care, known as “Post 
Intensive Care Syndrome”




destruction of the alveolar-capillary membrane,
secondary bacterial infections,
pulmonary fibrosis,” ground-glass opacity” [2, 3]
Cardiovascular palpitations, dyspnea and 
chest pain, high blood 
pressure, fatigue, swelling of 
the lower extremities, acute 
pain and discoloration of the 
arm or leg due to ischemia
Thromboembolic events. It is already known 
that many patients re-admitted to the hospital 
with chest pain and positive cardiac enzymes 
(Troponin, CK, CK-MB,) and high levels 
of D-dimer. Pulmonary embolism is very 
common. In patients at high cardiovascular 
risk or underlying ischemic heart disease, 
acute thrombotic occlusion of the coronary 
artery are diagnosed. Non-obstructive 
coronary heart disease has been verified in 
many patients: myocardial infarction with 
non-obstructive coronary arteries (MINOCA), 
endothelial dysfunction, and microcirculation 
of arterial vascular disease [9, 10]. Acute limb 
ischemia may be observed. Some patients have 
pericardial effusion or the development of 
dilated cardiomyopathy of viral origin, after 
myocarditis [10]
Gastrointestinal loss of appetite, weight loss, 
nausea, vomiting, diarrhea, 
abdominal pain
increased transaminases
dysbiosis in the intestinal microflora (disturbed 
microbiome) with, increase in pathogenic 
bacteria and decrease in the normal microflora in 
the gut [7]
Endocrine • new or worsening 




• Hyperglycaemia is due to a stress 
response of the body as a result of the 
disease as well as due to treatment with 
corticosteroids.
• lack of vitamin D and / or immobilization




decreased urine output, pain 
in the kidneys
elevated levels of waste products (urea and 
creatinine), requiring hemodialysis [2]
Reproductive 
system
Impaired spermatogenesis The male sex is more affected in reproductive 
system, and one of the hypotheses for this is 
the higher amount of ACE 2 in the male gonads 
compared to the uterus [11, 12]
Musculoskeletal 
system
occurrence of long-lasting 
arthralgia/myalgia
Due to immobilization, they can lead to cachexia 
due to loss of muscle mass. Sarcopenia - impaired 
muscle function due to loss of muscle tissue  
[2, 13]
Ear Nose Throat pain and “noise” in the ears, 
throat irritation, loss of taste 
and smell(anosmia)
Nasal congestion, pharyngeal erythema [14]
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1.5 Duration
Many global medical centers are opening specialized clinics to provide care 
for people who have persistent symptoms or related illnesses after COVID-19. It is 
important to know that most people who have COVID-19 recover. The scientific 
community should focus on that part of the people in whom the effects of the 
disease leave lasting traces and change their lives. It is still unknown how long PASC 
can last. In 30% of COVID-19 survivors, symptoms may persist indefinitely. Data 
show that 76% of patients reported persistence of at least one of the symptoms of 
PASC for at least six months after the acute phase [17]. Many COVID-19 survivors 
cannot return to their normal lifestyle. At this stage, there is no accurate scientific 
data on whether these long symptoms can lead to a chronicity of the condition.
1.6 Sequelae
Understanding the pathogenesis of PASC may provide answers to additional 
questions to guide the medical community to the right management of the 
condition.
The loss of human lives, the disability of the population, the increase in the  
costs of health care and services burden the health systems. Persistence of post 
COVID-19 conditions affects various levels of medical and social life, and the nega-
tive effects on healthcare and the economy may be fully appreciated in years to come.
The psychological and social consequences of ongoing Covid19 should be 
considered as part of clinical care models [17].
2. COVID-19 and the cardiovascular system
The primary target for SARS-CoV-2 is the respiratory tract, but the cardiovascu-
lar system can be involved too [18, 19].
As well as the mild flu-like symptoms, COVID-19 often causes serious damage to 
the cardiovascular system - pulmonary vascular endothelialitis, microangiopathy, 
diffuse thrombosis, cardiac arrhythmias, heart failure, myocarditis, pericarditis and 
acute coronary syndromes [19].
Once in the nasopharynx, the SARS-CoV-2 enters the body by binding through 
its S-binding protein to angiotensin I-converting enzyme 2 (ACE2) receptors, found 
mainly in the lungs, cardiac myocytes, and endothelial cells in the vessel wall [20].
ACE2 is known to have protective effects by counteracting angiotensin II and 
over activating renin-angiotensin-aldosterone system (RAAS), which occurs in 
conditions of cardiovascular disease (CVD) such as hypertension, congestive heart 
failure and atherosclerosis [19, 21].
System Symptoms Sign
Dermatology hair loss, skin rash, urticaria, 
dry skin
disturbed cycle in hair growth, (telogen 
effuvium);
stress after infection “COVID toes”  
syndrome - reddish-purple discoloration on 
the toes; In children, a rare condition similar to 
Kawasaki disease or Multisystem inflammatory 
syndrome in children (MIS-C) [2, 15, 16]
Table 1. 
Affecting the basic systems in post COVID-19 conditions.
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Entering through endocytosis, this RNA virus begins to replicate, causing wide-
spread infection. Since ACE2 converts angiotensin I and II to cardioprotective peptides - 
angiotensin 1-9 and angiotensin 1-7, its loss on cell surface may potentiate cardiac dam-
age, resulting in endothelial dysfunction, inflammation and thrombosis [21, 22].
ACE2 activity is known to be reduced in vessels with established atherosclerotic 
plaques and diabetes, while it is increased in women and young people due to the 
action of estrogens [21].
Decreased ACE2 activity may potentiate the so-called cytokine storm. This is an 
overreaction of the immune system caused by dysregulating RAAS and activating 
ACE2/bradykinin axis. The overproduction of cytokines and hyperinflammation 
leads to exacerbation of underlying cardiovascular diseases or triggering new ones.
According to the latest epidemiological data, about 80% of patients with COVID 19 
have mild symptoms, about 45% have symptoms requiring hospitalization, while 5% 
of patients need mechanical ventilation [21–25]. The difference in course is related to 
the degree of viral load, host immune response, age of the patient and the presence of 
concomitant diseases such as hypertension, diabetes and coagulation abnormalities.
Aging is associated with slowing of body functions, increased oxidative stress, 
reduced role of endogenous defense mechanisms. With age, reduced efficiency of 
thrombolysis, lower protection afforded by physical exercise against myocardial 
ischemia and more frequent manifestations of heart failure are more often observed 
[21, 22].
It has not yet been established whether the patient’s older age or greater immune 
response to the virus or both are responsible for myocardial damage with subse-
quent complications [21–24].
2.1 Cardiovascular complications in COVID-19
Direct viral infection, cytokine dysregulation and direct myocyte involvement 
can lead to acute myocardial injury in patients with COVID-19. Thus except for 
the high levels of CRP (C-reactive protein), elevated troponin levels suggest acute 
myocardial injury. It can be a result of myocarditis, ischemic injury, Takotsubo’s 
cardiomyopathy, septic cardiomyopathy, acute cor pulmonale (as a result of acute 
pulmonary embolism) [7, 26, 27].
Acute coronary syndromes can be a manifestation of imbalance between myocar-
dial supply and demand as a result of systemic changes – hypoxemia, tachycardia, 
hypotension, vasoconstriction; or acute thrombosis in the coronary arteries. Often, 
when the right coronary artery is affected a complete atrioventricular heart block 
can be seen. Other location of the coronary lesion may lead to severe ischemic car-
diomyopathy, left ventricular aneurysm formation with apical thrombosis [28, 29].
The most frequent arrhythmia seen in COVID-19 patients is atrial fibrillation, 
which is a result of the acute respiratory failure. Electrolyte imbalance – hypokale-
mia and hypomagnesaemia can also lead to arrhythmic states [30].
Some of the medications used in the treatment of COVID-19 have proarrhyth-
mogenic effects and should be used with caution, as they can provoke long QT 
interval, ventricular tachycardia and sudden cardiac death [30, 31].
A hypercoagulable state and thrombotic events, that are related to markedly 
elevated D-dimer and fibrin degradation products, are thought to be secondary to 
systemic inflammatory response [32, 33].
Takotsubo cardiomyopathy, predominantly seen in women, is mainly a result 
of increased sympathetic stimulation, which is usually observed in patients with 
COVID-19. It can be due to physical and psychological stress. This state can mimic 
acute coronary syndrome, which can develop within severe sepsis, hypoxemia, or 
metabolic acidosis [34–36].
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Acute myocarditis due to myocardial inflammation can lead to ventricular dys-
function as a result of focal or global myocarditis or necrosis [37]. Life- threatening 
arrhythmias can be a consequence of myocarditis. When linked with pericardial 
effusion, further deteriorating of the hemodynamics might lead to acute heart 
failure (HF) and cardiogenic shock [38, 39].
The pathogenic mechanisms and clinical manifestations of cardiovascular 
complications of COVID-19 are presented in Table 2.
Cardiovascular 
disease
Pathogenic mechanism Clinical manifestation
Acute coronary 




instability, imbalance between 
cardiac supply and demand
Typical chest pain or atypical pain and/or 
dyspnea, elevated levels of troponin, ECG 
changes (ST elevation or depression) and 
LV WMAs associated with specific region 
of distribution of a coronary artery
Myocarditis Cytokine storm, direct cellular 
damage (possible)
Chest pain (possible), dyspnea (possible), 
elevated levels of troponin, ECG changes 
(possible), diffuse LV WMAs not related 
to specific coronary artery territory 
distribution
Pericarditis Cytokine storm, direct cellular 
damage (possible)
Chest pain, dyspnea (possible), elevated 
troponin, ECG changes, impaired LV 
diastolic function and/or pericardial 
effusion
TTS Emotional stress, microvascular 
and endothelial dysfunction, 
sepsis, acidosis, hypoxemia
Chest pain and/or dyspnea, elevated 
troponin, ECG changes, LV WMAs 
not related to specific coronary artery 
territory distribution (circumferential 
pattern, apical ballooning most 
frequently)
PE Hypercoagulability Chest pain and/or dyspnea, perioral 
cyanosis, elevated troponin (possible), 
ECG changes - S1Q3T3 pattern (possible), 
RV enlargement and dysfunction 
(McConnell sign, 60/60 sign)
Decompensated 
chronic HF
Hypoxia, elevated metabolic 
demand
Dyspnea, fatique, orthopea, 
tachydyspnea, hepatomegalia, anasarca, 
elevated levels of troponin (possible), LV 
WMAs without de novo abnormalities
Acute myocardial 
injury
Cytokine storm, direct 
cellular damage (possible), 
microvascular and endothelial 
dysfunction, hypoxia
Chest pain and/or dyspnea (possible), 
elevated levels of troponin, ECG changes 
(possible), LV WMAs (possible) not 
associated with specific coronary artery 
territory distribution (if absence of 
coexistent CAD)
Arrhytmias Electrolyte abnormalities and 
medications for treatment 
of COVID 19 that have 
proarrhythmic effects
Dyspnea and chest pain (possible), ECG 
changes
ACS, acute coronary syndrome; CAD, coronary artery disease; CMR, cardiac magnetic resonance; CT, computed 
tomography; ECG, electrocardiogram; HF, heart failure; ICA, invasive coronary angiography; LV, left ventricular; 
PE, pulmonary embolism; RV, right ventricular; TTE, transthoracic echocardiography; TTS, Takotsubo syndrome, 
WMAs, wall motion abnormalities. Modified from Ref. [40].
Table 2. 
Pathogenetic mechanisms and clinical presentations of cardiovascular complications seen in patients with 
COVID-19.
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2.2 Imaging of cardiovascular complications
As COVID 19 is an infectious disease clinicians should use methods of imag-
ing, minimizing the risk of spreading infection. Most suitable are transthoracic 
echocardiography and point of care ultrasound. They are the first-line cardiac 
imaging techniques in this clinical setting, due to its portability, bedside feasibility 
in emergency settings and low cost [41].
The ultrasound is a diagnostic method for imaging the heart structures, valve 
lesions and kinetics. According to the European Association of Cardiovascular 
Imaging it is recommended performing echocardiography in patients with abnor-
mally high levels of cardiac biomarkers and/or ECG signs of myocardial damage, 
while acknowledging that other imaging diagnostic tests are not routinely used in 
the emergency context of the COVID-19 pandemic [42, 43].
Findings in echocardiography could be normal heart or uchanged from prior 
exams, global left ventricular dysfunction and strain, regional left ventricular 
dysfunction, right ventricuar dilatation, pylmonary hypertention and pericardial 
effusion.
CT scan and MRI can also be used for distinguising cardiovascular implication, 
but they have higher cost and lower availability [44].
2.3 Treatment of cardiovascular complications during acute COVID-19
Every hospital in the world should develop appropriate protocols for rapid 
diagnosis, triage, isolation, and management of patients with COVID-19 and con-
comitant cardiovascular complications. These protocols should be well-rehearsed for 
proper use of health services and to minimize the exposure of the medical staff [45].
Most of the patients with COVID-19 have hypertension, treated with ACE 
inhibitors or (ACEi) or angiotensin II receptor blockers (ARBs). The amount of 
cardiac ACE2 mRNA could be increased significantly by the use of ACEi and ARBs 
[46, 47]. However, major cardiology scientific associations, have recommended 
continuation of renin-angiotensin system inhibitors (RASi) in patients who have 
been prescribed them [47–49].
Statin therapy is important for patients with diabetes, history of stroke or chronic 
heart disease, and familial hypercholesterolemia. However, in cases with COVID-19 
there is still not an approved opinion whether it is risky or beneficial [50, 51].
As various anti-retroviral drugs might interact with cardiac drugs, a dose 
modification should be performed as well as careful monitoring [52]. Even though 
chloroquine or hydroxychloroquine could interfere with cellular endocytosis of the 
virus, prolongation of the QT interval might be observed. Therefore ECG monitor-
ing is crucial and should be done [52, 53].
Colchicine is a drug that has been shown to restrict the production of pro-inflam-
matory cytokines (tumor necrosis factor [TNF]-α, interleukin [IL]-1 and IL-6) and 
chemokines (IL-8), usually observed in patients with severe COVID-19 [54, 55].
As patients with COVID-19 may have elevated levels of D-dimer and higher 
platelet counts, it is suggested that coagulopathy is a major clinical feature in severe 
cases. This makes the use of anticoagulant and/or antiplatelet therapy very reason-
able [56, 57].
2.4  Long-term cardiovascular consequences as a part of the post COVID-19 
conditions
Most people recover completely from COVID-19, but some of them have persist-
ing symptoms after their initial recovery. This is the group of “long haulers” and 
Fighting the COVID-19 Pandemic
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the condition is called post-COVID-19 syndrome/conditions. [57, 58] The most 
common signs are fatigue, shortness of breath, cough, joint paint, chest pain. Every 
system could be affected, and the cardiovascular system is one of the frequent 
targets. Imaging tests taken months after recovery have shown lasting damage to the 
heart muscle [58–60]. This may increase the risk of heart failure or other complica-
tions such as arrhythmias and micropulmonary embolism. Careful follow-up of 
patients recovering from COVID-19 would be of great importance to understand 
the long-term impact of this illness [37, 61, 62].
3. “Life after COVID” campaign of the Bulgarian Cardiac Institute
Bulgarian Cardiac Institute is a leading organization for cardiovascular diagnosis 
and treatment in South-eastern Europe. The institute manages the largest and 
fastest growing medical group in Bulgaria. The medical establishments cover 2/3 
of the patient flow and ¾ from the territory of the country. The Bulgarian Cardiac 
Institute is unique in the development of modern scientific, educational and medi-
cal activities in the field of cardiology, cardiac surgery, neurology, neurosurgery, 
vascular surgery, oncology, surgery, orthopedics, genetics, immunology, radiation 
therapy and radiosurgery.
Despite the growing population of patients surviving COVID-19, the long-term 
consequences remain a clinical challenge. Currently, just under 1% of studies focus 
on Post COVID-19 conditions. That is why the Bulgarian Cardiac Institute has 
launched a large-scale, free-of-charge, voluntary and indefinite screening campaign 
“Life after COVID-19”. It aims to establish the effects of the infection on the cardio-
vascular system, diagnosis, treatment, long-term follow-up and adequate actions to 
improve the quality of life by providing specialized medical care.
The campaign covers citizens who have suffered from COVID-19. Those who 
wish to participate answer a survey with questions related to their health. When 
they answer in the affirmative to at least one of the questions (yes, i.e.there is a 
problem), we offer a free medical examination. It is held in one of the seven high-
tech hospitals, with the highest third level of competence, according to national 
medical standards or in one of the 15 medical centers in the country, by leading spe-
cialists in the field of cardiology. The initial examination includes a detailed history, 
complete examination, blood pressure measurement and electrocardiogram, on the 
basis of which we determine whether the patient needs additional instrumental or 
laboratory tests and treatment. According to the results and the leading symptoms, 
patients are consulted with trained in Europe and USA specialists in the field of 
cardiac surgery, neurology, neurosurgery, vascular surgery and others. If necessary 
and with persistence of symptoms, despite treatment, citizens are hospitalized.
As the population of recovering from COVID-19 grows, it is crucial to identify 
the health problems that surround them. The campaign creates round-the-clock 
access to high-quality and specialized medical care at European level, based on a 
multidisciplinary approach and dedicated medical care.
4. Initial results of the campaign “Life after COVID”
More than 1,500 citizens took part in the survey - 77% of them were treated at 
home, 23% were hospitalized, of which 2% in intensive care units. Of all respon-
dents, 80% answered in the affirmative (Yes, i.e.there is a problem) to at least 
one of the initial survey questions. Signs and symptoms such as fatigue (67%), 
palpitations (41%), shortness of breath (31%), chest pain (30%), joint pain (27%), 
9
Post COVID-19 Conditions and the Cardiovascular System
DOI: http://dx.doi.org/10.5772/intechopen.99197
headache (22%), impaired concentration (17%), persistent cough (16%), dizziness 
(15%) were among the most frequently reported in the questionnaire responses 
(Figure 1). A significant proportion of patients had more than two symptoms.
Medical examination was offered to citizens with persistent symptoms. We 
analyzed data from 808 patients (57% women and 43% men). The most common 
pathological changes we found were destabilization of blood pressure control (51%) 
- hypertension (92%), hypotension (5%) or fluctuation in blood pressure (3%). 
Heart rhythm disorders are the next most common finding (29%), expressed in 
tachycardia (97%) or bradycardia (3%). Manifestations of heart failure were found 
in 15% of cases.
According to the anamnesis and the objective condition, additional examina-
tions had to be performed in 65% of the examined. These examinations included:
• Instrumental methods: echocardiography (41%), holter ECG (3%), radiog-
raphy (3%)
• Laboratory diagnostics (9.4%): complete blood count, NT-proBNP, D-dimer, 
blood glucose test
• consultations with specialists (10%): neurologist (28%), pulmonologist (22%), 
endocrinologist (12%), vascular surgeon (5%), rheumatologist (4%) and other
At the end of the examination, a change in therapy was required for 62% of 
those followed.
At the time of the secondary examination, new studies were performed in 5% 
and a change in therapy in 2.6%. Despite all interventions, in 6% of the cases, due to 
the persistence of the symptoms, the citizens were hospitalized.
Our experience shows that the care of patients with COVID-19 should not stop 
at the end of the acute illness. From the responders to our survey, 4/5 reported 
persistent signs and symptoms months later. The most common complaints were: 
fatigue, palpitations, shortness of breath, chest pain. Other reported symptoms 
included joint pain, headache, and impaired concentration. High values of blood 
pressure, tachycardia, and manifestations of heart failure were the leading objec-
tive changes. Our study showed that in more than half of the cases of COVID-19, 
Figure 1. 
The most common signs and symptoms persisting after COVID-19.
Fighting the COVID-19 Pandemic
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additional tests and changes in treatment were required. The range of symptoms 
required the inclusion of doctors with different specialties in the overall follow-up. 
Despite the measures taken, the symptoms may be so severe and difficult to control 
that re-hospitalization may be necessary.
People suffering from post COVID-19 conditions constitute already a significant 
part of the world’s population, and their numbers will continue to grow. This neces-
sitates a long-term commitment of human and material resources and will test the 
health and economic system of the countries. Regardless of the obstacles we face, 
dedication and professionalism, good organization and a holistic approach are the 
main prerequisites for good results. By tracking and caring for these patients, we 
will not only contribute to increasing humanity’s knowledge of this new, dangerous 
pathogen, but we will also make progress in the process of diagnosis and treatment 
guidelines.
5. Imaging of myocardial involvement in post COVID-19 conditions
COVID-19 is a multiorgan systemic inflammatory disease caused by SARS-
CoV-2 virus. Patients with COVID-19 often exhibit cardiac dysfunction and myo-
cardial injury [63], which we can recognize with laboratory parameters and imaging 
methods. The most used imaging method is transthoraic echocardiography (TTE), 
which gives us information about the heart function. Global longitudinal strain 
(GLS) by speckle tracking echocardiography is an important additive method for 
evaluation of LV function at global and regional level. It is more sensitive method 
for detecting myocardial dysfunction, compared with Left ventricular ejection 
fraction (LVEF) [64]. Another very informative method is MRI, however it is not 
used that often, due to higher expenses and need of contrast material. According 
to studies, almost all patients with severe COVID-19 and most of the patients with 
moderate illness, had a certain degree of cardiac dysfunction [63].
Conventional echocardiography usually does not show significant changes in 
the LVEF and LV sizes in patients with mild or moderate COVID- 19. According to 
one trial in China, however, in 78.3% from the patients with mild infection and 98% 
of the patients who were in critical condition, some echocardiographic parameters 
showed deviations. For example, the motion of the LV walls was abnormal and 
the wall thickness was slightly thickened, particularly for the septum [63]. But 
in patients who were with critical conditions, lower LVEF could be found [65]. 
These changes are in correlation with elevated serum levels of cardiac biomarkers, 
such as cardiac troponin I (cTnI) and N-terminal pro-B-type natriuretic peptide 
(NT-proBNP), pulse oxygen saturation (SpO2) and inflammatory markers, such as 
C-reactive protein and cytokines [63].
Although abnormalities in conventional echocardiography are found mostly in 
patients with severe COVID- 19, global longitudinal strain (GLS) can identify sub-
clinical myocardial dysfunction. Moreover, measuring GLS gives us the opportunity 
for earlier diagnosis of myocardial injury, even before a reduction in the LVEF 
occurs. Studies showed that reduced LV-GLS is more frequent, occurring in 80% 
of the patients, while LV function parameters such as reduced EF and wall motion 
abnormalities were less frequent findings [66].
2D- speckle tracking echocardiography is a method, which evaluates myocar-
dial function at global and regional level. It shows the percentage of deformation 
between two points in the myocardium. Studies in COVID-19 patients show that the 
abnormal GLS predominantly involves the basal-septal and basal-lateral segments 
of the LV. This pattern reminded of a “reverse tako-tsubo” morphology, and is not 
typical for other viral myocarditis [67]. Another interesting finding is that the 
11
Post COVID-19 Conditions and the Cardiovascular System
DOI: http://dx.doi.org/10.5772/intechopen.99197
reduction of the LV-GLS is usually reversible, with normalization of the findings for 
one to three months [66].
Cardiac magnetic resonance (CMR) is the current gold standard to evaluate car-
diac morphology and function. It has higher sensitivity for detecting occult cardiac 
dysfunction than hs-cTnI. With its mapping techniques, such as T1, T2, extracellular 
volume (ECV) and Late Gadolinium Enhancement (GLE), this method can assess 
quantitatively diffuse or local myocardial fibrosis and edema [68]. One study in 
Frankfurt with 100 patients recently recovered from COVID-19, showed that 78% of 
them had abnormal CMR findings, namely lower left ventricular ejection fraction, 
higher left ventricle volumes, raised signals in native T1 and T2 mapping, which 
illustrate edema and changes in LGE, showing myocardial fibrosis. Endomyocardial 
biopsy was performed in patients with severe findings and revealed active lympho-
cytic inflammation [37].
Our experience in “Life after COVID” campaign (unpublished data) shows that 
about two-thirds of PASC patients referred for echocardiography have the typical 
post COVID-19 GLS impairment, involving predominantly the basal segments. 
We observe such findings in severe as well as non-severe COVID-19 cases. Our 
management strategy in these cases includes prolongation of antiaggregant therapy, 
initiation of cardioprotective therapy (could include some or all of the following: 
beta-blocker, trimetazidine, molsidomine), antiviral therapy (hydroxychloroquine) 
and advice to refrain from vigorous physical activity, although maintaining moder-
ate physical activity or inclusion in a rehabilitation program. Our initial experience 
with 3-month follow-up of these patients shows a resolution of the abnormality in 
about 80% of the cases in this time period.
From our experience, we think that global longitudinal strain is very sensitive 
for recognizing subclinical myocardial dysfunction and a valuable imaging method 
for prognosis, management, sport activity resumption advice, and long-term  
following of the patients recovered from COVID-19.
6. Acute coronary syndrome as part of the post COVID-19 conditions
Apart from the direct lung damage, the virus infection is associated with mul-
tiple organ damage, including the heart, causing conditions such as congestive heart 
failure, myocarditis, conduction abnormalities, arrhythmias, and acute coronary 
syndromes [69, 70]. The SARS-CoV-2 infection can frequently induce coagulation 
abnormalities that are associated with cardiopulmonary damage in all patients, 
despite presence or absence of concomitant risk factors and diseases.
The range of clinical responses to COVID-19 is extremely broad. Endothelial 
injury is an underlying mechanism that links the inflammation and consequent 
thrombosis [71, 72]. It is currently hypothesized that ACE-2 receptor is the entry 
gate for the virus to invade and infect tissues [73]. The vascular endothelium 
appears to be targeted directly by the virus as ACE-2 is expressed widely in the 
blood vessels and the heart. The result is exocytosis of endothelial granules contain-
ing VWF (von Willebrand factor), P-selectin, and other proinflammatory cyto-
kines, which mediate platelets adhesion, aggregation, and leukocyte adherence to 
the vessel wall, with a final result of intravascular thrombosis [74].
In addition, many patients with severe COVID-19 undergo thromboembolic 
events, due to this particular coagulopathy [75, 76]. One of the most and life-
threatening types of this coagulation abnormality is the one involving the coronary 
blood flow, thus causing a heart attack. In this scenario many additional problems 
arise – for example: access to a Cath lab, exposure of additional medical personnel, 
more complications and increased mortality for the patients. Invasive coronary 
Fighting the COVID-19 Pandemic
12
angiography for COVID-19 patients is a logistic challenge and, in some cases, there 
is not a need for intervention since the main problem is the thrombosis and the 
dysfunction of the microcirculation. For this reason, we evaluated in detail a case 
series of ten patients referred for primary percutaneous coronary intervention 
(pPCI) for MI in our catheterization laboratory during the course of COVID-19 
infection. The goal was to evaluate if there are any factors or parameters that could 
predict the presence of an interventional target – infarct related artery (IRA), prior 
to catheterization, and to determine their sensitivity and specificity.
During November and December 2020, 214 patients were treated in our COVID-
19 department. Ten of them were referred to the Cath lab with MI defined by the 
fourth universal definition [77]. Most of the patients in our study were sent to our 
hospital due to acute coronary syndrome, while others developed ACS during their 
stay in the COVID-19 department.
After coronary angiography, we found that 7 patients (70%) had an IRA, and 
they underwent pPCI. The other 3 (30%) did not have an IRA, they did not require 
pPCI, and the diagnosis of myocardial infarction with no obstructive coronary 
arteries (MINOCA) was made, most probably due to myocarditis or microvascular 
dysfunction.
Comparing the patients with IRA to those without we found that the subjects 
who required pPCI had significantly higher high-sensitivity troponin I(hsTRI) 
values, had typical chest pain, and had more often ST elevation. The other studied 
variables did not differ significantly between the groups with or without IRA. 
Regarding hsTrI concentrations, all but one patient with IRA and pPCI had 
hsTrI>7.5 times URL, and all patients without IRA and pPCI had hsTrI ≤7.5 times 
URLN. Therefore, for hsTrI>1.5 ng/ml (>7.5 times URL) to predict the presence 
of IRA and the need for pPCI the sensitivity is 86%, the specificity is 100%, 
positive predictive value (PPV) is 100%, while the negative predictive value 
(NPV) is 10%.
Even though our analysis is on a small number of patients, similar incidence 
of arterial (coronary and cerebral) thrombosis (4%) has been described by other 
authors. In this study, however, the authors have not provided a guide to the right 
moment of interventional treatment. According to our published data search, we 
were not able to find another study, analyzing the predictors for the presence of IRA 
and the need for pPCI in COVID-19 MI patients.
So in conclusion, myocardial infarction, could complicate up to 5% of COVID-
19 cases. In our study group, most of the patients (30%) with MI did not have an 
IRA and, did not need a coronary intervention. Patients with MI and IRA had 
significantly higher hsTrI values and exclusively typical chest pain compared to 
patients with MI but without an IRA, whose hsTrI values were lower and chest 
pain was atypical or non-stenocardic. ECG changes had only a minor statistical 
significance for distinguishing between MI patients with or without IRA. Our 
results suggest that using a higher cut-off value for hsTrI increases the specificity 
for diagnosing a MI and therefore - interventional treatment.
7.  Pulmonary thromboembolism in patients after COVID-19 - predictive 
indicators for correct diagnosis
Infection caused by SARS-CoV-2 has been shown to lead to significant proco-
agulant events, in some cases involving life-threatening pulmonary thromboem-
bolism (PE) [78]. A number of abnormalities have been described in coagulation 
parameters, which are a predictor of poor prognosis in patients with COVID-19 
and PE [79]. Due to the lack of large prospective studies, little is known about the 
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pathogenesis underlying PE, caused by COVID-19 [80]. Additional conditions 
complicating the diagnosis are the presence of risk factors for PE in almost all 
patients with COVID-19, as well as the overlap of the clinical presentation between 
PE and COVID-19.
We, therefore designed a study to find the indicators that predict the presence of 
PE in patients with acute or Post-acute COVID-19 conditions. It was a single-center 
study, conducted at the Heart and Brain Hospital, Pleven in the period December 
2020-February 2021. It included 27 consecutively hospitalized patients with recent 
pneumonia caused by Covid-19 and clinical presentation referring to PE. The 
cohort was divided into two groups - without and with a definitive diagnosis of PE, 
proven by CT pulmoangiography. During treatment with COVID-19, all patients 
received a prophylactic dose of anticoagulant and antiplatelet drug.
Our results showed that eight patients from the group had PE, and 19 had not 
evidence of PE. The mean age of the group was 65 years and 18 of the patients were 
women. Тhe two groups did not differ significantly in age and distribution between 
the sexes. Statistically significant differences in electrocardiographic findings were 
observed in the two groups. In patients without PE, 18 (94.7%) had no evidence of 
S-wave greater than 1.5 mm in I, aVL. On the other hand, in the group diagnosed 
with PE in 3 (37.5%) this ECG criteria was not present, and in 5 (62.5%) it was 
present (p = 0.004). Similar ratios were found in terms of the presence of Q-wave in 
III, aVF. In patients without PE, 18 (94.7%) did not have this ECG sign, while it was 
present in half of the patients with PE(p = 0.017).
In patients without PE, the median value of oxygen saturation was 92.0% (69-
97), and in those with proven - 88.5% (83-95) (p < 0.001). Statistically significant 
differences between the two groups were observed in regard to the indicator - the 
ratio RV/LV diameters ≥1.0 (p = 0.001). In patients without PE there was none 
with an increase in the ratio ≥ 1 in favor of the right ventricle, while in the group of 
patients with massive form 5 (62.5%) had the ratio RV/ LV diameters ≥1.0, and 3 
(37, 5%) did not have it. The same results were demonstrated for the indicator right 
ventricular dysfunction (p = 0.001). The RV/LV diameter ratios ≥1.0 as well as 
right ventricular dysfunction showed sensitivity 62.5%, specificity 100%, positive 
predictive value 100% and negative such 86.4% to verify the PE diagnosis.
D-dimer values  differed significantly in the two groups. In patients without 
PE, the mean D-dimer value was 1546 ng/ml (109-8840), while in those with 
PE - 6489.75 ng/ml (570-17051) (p = 0.021). For our laboratory, the upper limit of 
the normal range is 500 ng/ml. As a result of the ROC analysis we found that the 
D-dimer cut-off value of 1032 ng/ml (2,064 times higher above the upper limit of 
the normal range) had an optimal sensitivity (Se) of 87.5%, specificity (Sp) 57.9%, 
positive predictive value (PPV) 46.7% and negative predictive value (NPV) of 
91.7% for the diagnosis of PE (p = 0.021) (Figure 2).
Regarding D-dimer as a binary variable (cut-off 1032 ng/ml), we found that 
in the group without PE, in 11 (57.9%) of patients the D-dimer was ≤1032 ng/
ml, while in 8 (42.1%) it was >1032 ng/ml. Of the patients with massive PE, only 1 
(12.5%) had a D-dimer ≤1032 ng/ml, and the remaining 7 (87.5%) were > 1032 ng/
ml (Fisher’s exact tests, p = 0.043).
When performing binary logistic regression, part of the ECG criteria - S-wave 
over 1.5 mm in I lead and aVL (p = 0.007), Q-wave in III and aVF (p = 0.020), as 
well as the D-dimer as quantitative variable (p = 0.025) proved to be independent 
predictors of PE.
Our results show that against the background of acute and Post-acute COVID-19 
conditions ECG and EchoCG criteria remain predictive of PE. As for the D-dimer 
values, we found that a cut-off concentration with optimal Se, Sp, PPV and NPV for 
diagnosis of PE, is two times higher than the upper limit of normal, with high Se and 
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NPV. We suggest that a higher D-dimer cut-off value should be applied in COVID-19 
and post-COVID-19 patients in order to confirm/dismiss the diagnosis PE.
8. Acute limb ischemia as part of the post COVID-19 conditions
The vascular bed, being rich in ACE2 receptors, is not devoid of complications 
during the acute or post-acute COVID-19 conditions. Our analysis is to report 
our experience in the Department of Vascular Surgery of Heart and Brain Center 
of Clinical Excellence, Pleven, Bulgaria, focusing on management of COVID-19 
patients who developed severe acute ischemia with impending lower and upper 
limb loss.
We carried out a retrospective data collection of COVID-19 patients with severe 
acute ischemia of the lower or upper limbs between December 2020, and April 
2021. We included only those COVID-19 patients suffering from acute lower limb 
ischemia. Primary outcomes of the analysis were early reoperations, amputation 
and postoperative mortality.
Admitted to our department were 16 patients (13 male, 3 female) with acute 
ischemia of the lower limbs and 2 patients (both male) with acute ischemia of the 
upper limbs. The median age was 70 years (range 50–85 years). All patients tested 
positive for COVID-19 and all had general clinical symptoms. In all patients, the 
limb was at risk, and the only alternative was a major amputation. Seven of the 
cases had previous claudication symptoms and peripheral artery disease (PAD). 
Computed tomography-angiography (CT-A) showed acute thrombosis over athero-
sclerotic occlusive disease. The rest of the patients [11] had no clinical evidence of 
PAD. The occlusion was related to acute thrombosis of the arteries or distal emboli-
zation and confirmed by (CT-A).
Generally, based on the patient’s overall stability, degree of ischemia, and limb 
viability, a determination needs to be made whether intervention is appropriate, 
Figure 2. 
ROC analysis for D-dimer values and the probability of PE.
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and if so, whether an endovascular or open approach should be used. It is crucial 
to consider the severity of systemic illness when considering intervention. Because 
of the severe pulmonary complications associated with COVID-19, critically ill 
patients may not be candidates for revascularization. Similar to damage control in 
trauma patients, the principle of “life over limb” is justified.
Laboratory parameters in our group showed increased levels of serum D-Dimer, 
C-reactive protein (CRP), and a decreased platelet count. All 18 patients underwent 
urgent revascularization, (embolectomy, open surgery procedures, percutaneous 
transluminal angioplasty with catheter balloon and stenting or primary amputa-
tion). Postoperatively, all patients received heparin therapy with low molecular 
weight heparin, combined with clopidogrel 75 mg and, in some cases, acetylsalicylic 
acid 100 mg.
Ten of the patients suffered from early (1st or 2nd day) postoperative re-throm-
bosis. All of them underwent reoperation (embolectomy), but 6 of them suffered 
from re-re-thrombosis and eventually required above-the-knee amputation and one 
patient required above-the-elbow amputation. Unfortunately, 7 patient died from 
multiple organ failure (MOF). 11 patients left the hospital in generally good condi-
tion. One patient with femoral-popliteal thrombosis left with symptoms of claudi-
cation but without critical limb ischemia. After one month this patient underwent 
endovascular revascularization with percutaneous transluminal angioplasty (PTA) 
and stent implantation (Table 3).
9. Conclusions
In our experience, the incidence of acute limb ischemia increased significantly 
during the COVID-19 pandemic in Bulgaria. Successful revascularization and 
survival was lower than expected, which we believed was due to a virus-related 
hypercoagulable state. The use of prolonged systemic heparin might improve surgi-
cal treatment efficacy, limb salvage, and overall survival.
10. Cardiac surgery during the COVID-19 pandemic
The COVID-19 pandemic posed serious challenges not only to modern cardiac 
surgery, but to medicine in general. As a result of the epidemic situation, the 
planned admission to hospitals and elective operations were stopped, and some 
of the health facilities were transformed into COVID-19 centers. Our hospital has 
developed a special algorithm for admission of patients in need of urgent or emer-
gent cardiac surgery.
All procedures Generally good condition Mortality
All patients 18 11 (61.1%) 7 (38.9%)
Open surgery 15 8 (53.3%) 7 (46.7%)
PTA/Stent 3 3 (100%) 0 (0%)
Re-operation 4 3 (75%) 1 (25%)
Amputation 6 3 (50%) 3 (50%)
Table 3. 
Operative vascular procedures at the Vascular Surgery Department of Heart and Brain Center of Clinical 
Excellence, Pleven, Bulgaria
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The epidemic situation has led to a reduction in hospital admissions. One of 
the reasons is certainly the fear of intra-hospital infection and transmission of 
COVID-19. The other reason is the postponement of elective operations. According 
to statistics, the number of hospitalized patients with acute coronary syndrome 
has decreased by 30%. If we consider that the mortality from COVID-19 is about 
3% and the mortality from untreated STEMI reaches 30%, then the fear seems 
unjustified [81]. Important in this case, from a cardiac surgery point of view, is the 
definition of the concepts of elective and emergency admission and treatment, as 
well as treatment in accelerated and urgent order, as well as the nosological units to 
the respective groups:
• True elective (isolated MR, isolated AS)
• Accelerated elective (AS combined with CAD)
• Urgent (CAD withLM disease or LM equivalent)
• Emergent (Infective endocarditis, Acute myocardial infarction)
• Salvage life saving (Aortic dissection Stanford type A, mechanical complica-
tions after AMI)
While the first two groups may remain on the waiting list, for the next three the 
waiting time is shortened according to the disease (24 hours, 6 hours and as soon 
as possible in case of urgent, emergency and life-saving surgery, respectively). The 
functioning of such a system requires particularly good communication and col-
laboration between GPs, specialized outpatient and inpatient care, proper categori-
zation of patients and optimal timing of treatment.
Unfortunately, there is still no formal international protocol or guidelines for 
optimal timing of cardiac surgery in patients with active COVID-19 infection. 
Since the beginning of the pandemic, 18 patients with identified COVID-19 infec-
tion pre- or postoperatively have undergone cardiac surgery (4.9% of all operated 
patients). The results of the operative treatment are excellent, as the intraoperative 
and early (up to 7th day) postoperative mortality is zero. Late postoperative mortal-
ity was 44%, with no patients dying from cardiovascular disease. It is noteworthy, 
contrary to expectations, that it is not the complexity of surgical treatment that is 
the leading risk factor for the complicated postoperative period in patients with 
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proven COVID-19, but the development of viral pneumonia. Interstitial changes 
typical of COVID-19 pneumonia (ground-glass opacities, vascular enlargement, 
bilateral abnormalities, lower lobe involvement, and posterior predilection) have 
been demonstrated by CT scan in 75% of the deaths, with respiratory failure being 
the leading cause of death.
The question how long after recovery from a COVID-19 infection can a patient 
be transferred to surgery also remains open. Several studies on the subject are cur-
rently conducted. The data collected so far from 116 countries on 140,231 patients 
may finally show some resolve [82]. 2.2% of the patients included in the study were 
diagnosed preoperatively with COVID-19 infection. Mortality is highest in the first 
7 weeks after the illness.
Thus, with surgical treatment 0-2 weeks, 3-4 weeks, and 5-6 weeks after 
COVID-19, the 30-day mortality was 4.1%, 3.9% and 3.6%, respectively. In surgical 
treatment after the seventh week, the results were the same as in patients without 
COVID-19 infection (1.5%). The estimated 30-day postoperative mortality in 
patients without COVID-19 infection was 1.5%. It should be borne in mind, how-
ever, that these are not specific studies in the field of cardiac surgery, but concern 
surgery in general. Probably the specific risk for cardiac surgery patients would be 
higher if we consider the complicated procedure of cardiac surgery, the aging of 
the population and the polymorbidity of the Bulgarian population. The role of the 
Heart team is crucial and the preparation of precise general hospital protocols and 
individual approach to each patient are extremely important for achieving good 
results.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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